Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj ® (revumenib) was named Best New Drug at the ...
KOMZIFTI (ziftomenib), the first and only once-daily oral menin inhibitor for adult patients with R/R AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options, has ...
December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on ...
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own ...
Japan’s MHLW grants Pioneering Regenerative Medical Product Designation to AskBio’s AB-1005 and AB-1002: Berlin, Germany Wednesday, December 10, 2025, 12:00 Hrs [IST] AskBio I ...
Upregulation of endothelin-1 is considered an important contributor to the pathophysiology of CKD progression, including increased blood pressure, glomerular membrane permeability, mesangial cell ...
Feline HCM remains a complex, prevalent, and often-devastating disease. While cats can remain asymptomatic for years, progression to CHF or thromboembolism can be sudden. A structured approach to ...
Berlin, Germany, and Research Triangle Park, N.C., USA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Not intended for UK Media Product designation supports development of innovative investigational gene ...
Strategies for finding the best deal if you have health issues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback